cyrilzakka/clinical-trials huggingface dataset:
The Impact of Interpretation Bias Modification Training on Anger and Reactive Aggression

Difficulties with anger control are reported in a number of psychological conditions and are associated with social problems, such as dating violence and workplace violence. High trait anger is a personality construct characterized by elevations in the frequency, duration, and intensity of anger episodes. However, the cognitive processes contributing to high trait anger are still poorly understood. This study will examine the effectiveness of a computer-based cognitive bias modification (CBM) program designed to target hostile interpretations associated with high trait anger.

High trait anger is a personality construct characterized by elevations in the frequency, duration, and intensity of anger episodes. According to the Integrative Cognitive Model (ICM) of anger, three cognitive processes jointly contribute to an individual's level of trait anger and reactive aggression: hostile attributions, ruminative attention, and effortful control processes. Specifically, individuals high in trait anger are more prone to interpret ambiguous situations as hostile; are more likely to ruminate about anger-related events; and have a more limited capacity to employ control processes when they become angry.

One means of evaluating unconscious biases that has become increasingly popular is cognitive bias modification (CBM). CBM programs are computerized training paradigms, which aim to train more adaptive cognitive biases by repeatedly exposing participants to an experimental contingency between an emotional stimulus and a response.Previous researchers have begun to investigate the impact of CBMs targeting cognitive control and hostile attribution bias in relation to anger. However, these studies have been conducted exclusively in samples reporting low trait anger.

This study will examine the effectiveness of a short-term interpretation bias modification program (CBM-I) on hostile attribution biases and reactive aggression in a sample of undergraduate students eporting high trait anger.

Eligibility Criteria:
Inclusion Criteria:

1. Students scoring 22 or higher on the Trait Anger Scale.

Exclusion Criteria:

1. Reports currently receiving psychological treatment or counseling for anger.
2. Reports changes in psychiatric medication within the last month.
3. Endorsement of current psychosis or bipolar disorder symptoms.
4. Indicates poor English language proficiency.
Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.

Despite good initial response, some patients with core binding factor and/or NPM1-mutated AML eventually relapse. Some of these patients can be identified earlier on, before overt cytological relapse, when followed for minimal residual disease. The outcome of patients treated when molecular relapse is confirmed, before overt cytological relapse, is not well known. This multi-center retrospective will therefore study the outcome of these patients and try to specify the role of allogeneic stem cell transplantation in this setting.


Eligibility Criteria:
Inclusion Criteria:

* Patients between 18 and 61 years
* Diagnosis between 2010 and 2019
* Core binding factor and/or NPM1 acute myeloid leukemia
* First complete remission after induction therapy
* Measurable residual disease measurement after end of consolidation therapy

Exclusion Criteria:

* Acute promyelocytic leukemia
* Allogeneic stem cell transplantation in CR1
Pregabalin In Partial Seizures Extension Study

To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.


Eligibility Criteria:
Inclusion Criteria:

* met the inclusion/exclusion criteria for A0081005
* have completed the 21-week study and have shown a significant clinical response and wish to continue treatment

Exclusion Criteria:

* Having a treatable cause of seizure.
* Having a progressive neurological or systemic disorder
High-Protein Food Snack for Dialysis Patients

The study team aims to provide a food snack that is high in protein (30 g) for two weeks each month (6 treatments per patient per month) for 6 consecutive months, post-dialysis treatment, to in-center hemodialysis patients of all vintages and with all levels and types of comorbidities. The study team will compare changes in serum albumin during the intervention (6 months) using the patients' own serum albumin results that are collected for three months prior to and three months after the intervention. Additionally, the study team will determine participants' dietary habits and appetite pre-, during and post-intervention.


Eligibility Criteria:
Inclusion Criteria:

* Chronic Hemodialysis (CHD) therapy
* Active and permanent patients to the area Fresenius Kidney Care (FKC) Dialysis clinic
* No food allergies or dietary restrictions
* No contraindications to consuming anything by mouth as per the medical director and/or personal reporting.

Exclusion Criteria:

* Patients unable to commit to the full time commitments of the study
* Those who have food allergies, especially to Chicken, Pork Sausage, Eggs, Fresh Cilantro, Red and yellow bell peppers, Cucumbers, Mrs. Dash Grill Seasoning, Newman's Own Ranch Salad Dressing, Minced garlic, Sweet pickle relish, Vidalia onions, tomatoes
* Dietary restrictions as medically indicated,
* Trouble chewing/swallowing as confirmed by medical director, and/or personal reporting.
Evaluation of the Effect of Biofiller PRP Application on Knee Osteoarthritis

The aim of this study is to evaluate the effects of biofiller PRP, on pain, range of motion, quality of life, and femoral cartilage thickness in patients with knee osteoarthritis.

Patients who are admitted and diagnosed with knee osteoarthritis based on anamnesis, physical examination and imaging methods are included in the study

Eligibility Criteria:
Inclusion Criteria:

1-45-65 years old 2-Diagnosis of knee OA according to ACR clinical and radiological diagnostic criteria 3-Kellgren Lawrence stage II or III 4-Knee pain for at least 6 months 5-Visual analog scale (VAS) score of at least 3 or more

Exclusion Criteria:

1 - History of surgery or traumatic injury 2-Inflammatory arthritis 3-History of cancer, bleeding diathesis and psychiatric disease 4-Those who have a disease that limits their participation in exercises (severe chronic obstructive lung disease, severe heart failure, history of cerebrovascular events) 5-Hip and ankle problems 6-Participating in another physical therapy program in the last 3 months 7-History of intra-articular injections in the last 6 months
Fresh Lime Alone for Smoking Cessation

The purpose of this study is to determine whether fresh lime alone is effective for smoking cessation.

Smoking is the major preventable cause of chronic medical diseases and death worldwide. Significant efforts led by World Health Organization (WHO) and several countries have been made to help current smokers to quit, particularly in the developing countries, where their smoking rates continued to rise. Clinical practice guidelines were therefore developed to guide all healthcare personnel in those countries to provide treatment for smokers. However, despite that, only a small number of smokers were able to quit successfully. A large number of smokers who are poor and heavily addicted to nicotine remain and have no access to any effective smoking cessation aids. Although there are several effective medications available for smoking cessation nowadays, the high price of them completely keeps poor smokers away from using them. Alternative and cheaper smoking cessation aids are therefore necessary. During the past decade, certain herbal remedies have been introduced in smoking cessation in Thailand. One of them that have been used widely without any supporting evidence is the fresh lime (Citrus aurantifolia), the well-known native citrus to Southeast Asia. It is anecdotally claimed to be effective and safe in smoking cessation. The present study was designed to determine the efficacy and safety of fresh lime as a smoking cessation aid compared with those of nicotine gum.

Eligibility Criteria:
Inclusion Criteria:

* Age over 18
* Smoked regularly at least one year prior to study entry
* Had the desire to quit smoking
* Signed informed consent

Exclusion Criteria:

* Having current dental problems
* Active peptic ulcer disease
* Psychiatric disorders
* Citrus allergy
* Pregnancy
* Use of illicit drugs
* Participation in another clinical trial and/or using any first-line smoking cessation aids within the past 30 days
Assessment of Sleep Disordersin People Living With HIV in the Era of New Antiretroviral Therapies in North of France

People living with HIV (PLHIV) appear to present with sleep-related complaints more frequently than the general population, with a prevalence of 50-70%. The latest French multi-center epidemiological data are dated. The prevalence of the different types of sleep disorders, however, is poorly documented, with the literature focusing mainly on insomnia and neuropsychological disorders that can lead to sleep disorder-like symptoms, and on the impact of antiretroviral drugs in particular. However, there are other sleep disorders such as sleep apnea syndrome (SAHOS) or restless legs syndrome. SAHOS has been studied in small series of patients.

This multicenter, cross-sectional study will identify and update the functional complaints presented by PLHIV, estimate the prevalence of people at high risk of sleep apnea syndrome, and study the associated socio-demographic factors, in relation to HIV infection and antiretrovirals. This study could open up avenues for new management approaches and earlier detection of sleep disorders.


Eligibility Criteria:
Inclusion Criteria:

* PLHIV usually treated at referral centers in northern France.

Exclusion Criteria:

* Minor patient;
* Patient with insufficient understanding of the French language, as judged by the investigator;
* Patient unable to give free and informed consent;
* Refusal to participate;
* Patient under legal protection, guardianship or curatorship;
* Pregnant and breast-feeding women.
A Real-World Registry to Investigate the Performance of LenSx® Laser in Chinese Patients

The purpose of this study is to investigate the performance of LenSx® Laser in femtosecond laser-assisted cataract surgery (FLACS) in real-world medical practice in Chinese patients.

All subjects will undergo FLACS using the LenSx® Laser system. The recommended postoperative visits will follow the current standard of care in China.

Eligibility Criteria:
Inclusion Criteria:

* Chinese;
* Will undergo LenSx® Laser-assisted cataract surgery and phacoemulsification in at least one eye;
* Must sign written informed consent;
* Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

* Contraindications listed in LenSx® Laser System Operator's Manual;
* Pregnant, nursing, or planning a pregnancy;
* Concurrent enrollment in another investigational drug and/or device study or participation in such a study within 30 days prior to surgery day;
* Other protocol-specified exclusion criteria may apply.
Uterine Contractions Under Blue Light

The objective in the current study is to test the hypothesis that nocturnal uterine contractions in preterm women can be suppressed by brief ocular exposure to blue light.The Olcese lab at Florida State University identified a novel interaction between the myometrial melatonin receptors and OT receptors in human myometrial cells (Sharkey et al. 2009), which may ultimately help to resolve certain issues surrounding idiopathic preterm labor. Their results consistently indicate that melatonin at physiological concentration sensitizes human myometrial smooth muscle cells to the contractile effects of OT (Sharkey et al. 2010).

Study participants will be pregnant women (gestational weeks 24 to 31+6 days) who present with preterm contractions. In the triage room, the study participant will be connected to the external tocometer from at least 19:00h (7 PM) to the following morning at 07:00h. Room lighting will be kept dim.

Participants meeting inclusion criteria will be randomly allocated to blue light or red light. Baseline contractions will be measured. The allocated light mask will be applied for 2 intervals of 60 minutes each.There will be a 60 minute rest period after every 60 minute intervention period for comparison.

Other than the application of the light mask, all routine standards of care deemed warranted by the obstetric provider for proper treatment of preterm labor will be followed. (ie antenatal steroids, tocolytics).

Eligibility Criteria:
Inclusion Criteria:

* Pregnant
* Gestational age: 24 to 31 (+6 days) week of pregnancy
* Uterine contractions
* First episode of preterm labor

Exclusion Criteria:

* Visual impairment (legally blind)
* Multiple pregnancy
* Current progesterone treatment
* Preeclampsia
* Renal disease
* Current chlamydia or gonorrhea infections
* Cocaine or opiate use
* Nightshift work in the past week
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.


Eligibility Criteria:
Inclusion Criteria:

* Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
* At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
* Clinical lab results within the normal range

Exclusion Criteria:

* Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.
* Treatment with systemic immunosuppressive medications or biologics.
* Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate (S1P) receptor modulator, compared to the rates of these events in two population of participants:

* Participants not exposed to ozanimod with RRMS who have received treatment with other S1P-receptor modulators disease modifying treatments (DMTs)
* Participants not exposed to ozanimod with RRMS who have received treatment with other non-S1P-receptor modulators disease modifying treatments (DMTs)


Eligibility Criteria:
Inclusion Criteria:

* Have a diagnosis of multiple sclerosis (MS) recorded on or before the index prescription
* Have at least 6 months of continuous enrollment in the data source (thereby providing medical and dispensing/prescription history data, along with an operational definition of new use) before the index date

Exclusion Criteria:

• Participants with dispensing/prescription of more than one cohort defining drug on the index date

Other protocol-defined inclusion/exclusion criteria apply
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis

Migration Inhibitory Factor has proliferative and antiapoptotic actions on fibroblasts which may be relevant to scleroderma because of the central role of a dysregulated fibroproliferative response in disease-affected tissues

* Systemic sclerosis (scleroderma) is a disease of unknown etiology characterized by fibrosis of the skin and internal organs, pronounced vasculopathy, and dysregulated immune system.
* Clinically, the disease is divided into 2 major subsets, diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc). The diffuse cutaneous subtype is generally associated with significant internal organ involvement, especially renal crisis and diffuse alveolitis of the lung, along with antitopoisomerase (antitopo) autoantibody. The limited cutaneous subtype is distinguished by Raynaud's phenomenon, telangiectasias, pulmonary hypertension, and the presence of anticentromere antibody. However, there is significant overlap both in the clinical manifestations and in the specific autoantibodies that occur in these subtypes. It is not known what predisposes a susceptible individual to develop one subtype versus another, nor is there significant information about how the 2 disease subtypes may be pathogenically related.
* Activation of T lymphocytes and macrophages is an early event in the parthenogenesis of SSc. Activated T cells , macrophages and endothelial cells are important sources of Macrophage Migration Inhibitory Factor MIF was initially identified as the protein secreted by activated T lymphocytes capable of inhibiting random migration of macrophages, concentrating macrophages at inflammation loci, and enhancing their ability to kill intracellular parasites and tumoral cells.
* Migration Inhibitory Factor has proliferative and antiapoptotic actions on fibroblasts which may be relevant to scleroderma because of the central role of a dysregulated fibroproliferative response in disease-affected tissues.
* In patients with SSc, elevated serum levels of MIF, increased MIF expression in the skin and afunctional promoter polymorphism in the MIF gene that might influence clinical expression have been described therefore MIF might have an important role in the disease.

Eligibility Criteria:
Inclusion Criteria:

-Patients with Systemic Sclerosis .

Exclusion Criteria:

* Patients with Interstitial Pulmonary Fibrosis caused by causes other than SSc.
* Other rheumatologic diseases.
* Overlap or Mixed diseases.
* Patients with renal disease caused by causes other than SSc.
* Unwillingness to participate in the study.
Assessment of Recombinant HAT-RDT Specificity

Human African trypanosomiasis HAT, or sleeping sickness, is a tropical disease caused mainly by the parasite Trypanosoma brucei gambiense (gHAT). After a severe epidemic in the 1990s, the World Health Organization (WHO) now targets elimination of transmission of gHAT by the year 2030, which heavily relies on its diagnosis and treatment. Traditional screening tests (like CATT or rapid diagnostic tests (RDTs)) are based on the detection of antibodies against the parasite using native antigens, which are costly and dangerous to produce. New serological tests, using recombinant antigens, have been developed, but little is known about their field performance. The primary objective of this study is to assess the specificity of the newly-developed recombinant RDTs, since it will become very relevant as we move forward towards a screen\&treat strategy. We will also compare the diagnostic accuracy and overall performance of iELISA and molecular testing.

This prospective study will follow two different mobile units as they go on their routine screening of the gHAT endemic population. Study participants will be enrolled during the routine screening, and after providing informed consent, they will be asked for a 4.5 ml venous blood sample. The three RDTs (HAT Sero-K-SeT, rHAT Sero-K-SeT, Bioline HAT 2.0) and CATT will be performed on site, while part of the sample will be mixed with DNA/RNA Shield for molecular analysis and the rest will be left to decant, to collect plasma for iELISA and TL. Confirmatory tests will be performed in the field on any seropositive individual. Should any case be confirmed, treatment will be offered, free of charge, following PNLTHA guidelines.

The obtained data will allow for a very precise estimation of the specificity of the newly developed recombinant RDTs. This study does not aim to determine the sensitivity of these tests since, due to the very low prevalence, the chance of having sufficient seropositive samples and/or finding a true case are very slim. The diagnostic performance of iELISA and novel molecular tests will also be determined.

Eligibility Criteria:
Inclusion Criteria:

* Willing and able to provide written informed consent (and assent for minors 12-17years old)
* Be enrolled in routine HAT screening activities dony by the mobile unit (PNLTHA mobile unit routine active screening teams that visit villages at risk for HAT). People living in the village are targeted for screening.
* Participants must be at least 12 years old

Exclusion Criteria:

* Chilrden younger than 12 years old
* previously treated for HAT
* refusal to provide informed consent
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.

Despite long-term outcomes of kidney and liver transplantation significantly improved in the last decades, high morbidity and mortality is still an issue at short term after transplantation. Specifically, occurrence of delayed graft function (DGF) and early acute rejection (AR) may cause multi-organ failure or graft failure, admission to intensive care unit, prolonged hospitalization and high-dosage immunosuppressive therapy which might expose patients to several further complications such as infections, neoplasm, and metabolic disease. Consequently, solid organ transplant recipients represent a very frail population at high risk of complications. Therefore, development of new biomarkers for the prevention and early diagnosis of the major post-transplant complications influencing the morbidity and mortality of solid organ transplant recipients are needed. Adrenomedullin (ADM) is a 52-amino acid peptide with a variety of physiologic functions such as immunemodulating activity, direct bactericidal activity, maintenance of renal homeostasis, and vasodilatory activity. Recent study has shown that midregional proADM (MR-proADM) is co-synthesized with ADM in equimolar amounts and has the advantages of a longer half-life, lack of bioactivity and lack of protein binding. MR-proADM has been recognized as a prognostic marker, stratifying the mortality risk in patients with sepsis in intensive care units. Moreover, recently MD-proADM has been also associated with risk of specific organ failure such as acute kidney injury, acute liver damage, acute respiratory distress syndrome and acute cardiac injury. Literature results suggest that recovery of graft function after KT may lead to decrease in plasma MR-proADM level in patients with ESRD, and that plasma MR-proADM level may could increase in the early phases of DGF and AR after KT and LT as a response damage and to the immune activation. The study will allow to evaluate the utility MR-proADM as an early biomarker of DGF and AR in patients undergoing kidney and liver transplantation at our Institution. Also, the study aims to analyze how the value of this biomarker can change in association with post-transplant complication and to create a predicting model by machine cut-off values of references for MR-proADM.

Eligibility Criteria:
Inclusion Criteria:

* Kidney transplant recipient at our Institution
* Liver transplant recipient at our Institution

Exclusion Criteria:

* Re-transplantation
* Dual kidney transplantation
* Combined transplant (kidney-liver, kidney-pancreas)
* Autoimmune disease as indication to transplant